Wesana Health Holdings Inc. announced the commencement of functional animal studies to determine effect of a psilocybin-based regimen on locomotor activity as well as anxiety and depression. Results from the anxiety and depression study are expected by early fourth quarter of 2021. The functional animal studies come on the heels of a recently completed retrospective Pilot Study to gather quantitative data pertaining to user experiences with components of a combination therapy for treating mild to moderate traumatic brain injury, anxiety and/or depression related to previous TBI and migraine headaches unrelated to TBI. Based on learnings from the Pilot Study, a Pivotal Study is scheduled to begin in August 2021 and conclude in late third quarter of 2021.